What is Thalomid?
Thalomid is an immunomodulatory agent (a drug that affects the immune system) that was originally developed in the 1950s as a treatment for insomnia and morning sickness. Further research on Thalomid showed it to be highly active against myeloma. When the findings of that research were published in 1999, Thalomid was considered to be the first new agent with major activity against myeloma in more than 30 years.
Thalomid is a brand of thalidomide manufactured by The Celgene Corporation.
To ensure that Thalomid is used safely, Celgene has developed a unique restricted distribution program called S.T.E.P.S. (System for Thalomid Education and Prescribing Safety). Individuals eligible to receive Thalomid must be registered in S.T.E.P.S., and the doctor writing the prescription and the pharmacy filling it must also participate in the program. This program is designed to minimize the chance of fetal exposure to Thalomid.